dasatinib

Also known as BMS 345825, BMS 354825, BMS 35482513, Sprycel®, anh. dasatinib, dasatinib (anh.), anhydrous dasatinib, BMS-354825

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

Chemical data

Formula: C22H26ClN7O2S
Molecular weight: 488 g/mol
IUPAC name: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
SMILES: CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
InChIKey: ZBNZXTGUTAYRHI-UHFFFAOYSA-N
XLogP: 3.6
Polar surface area: 135 Å²
H-bond donors: 3
H-bond acceptors: 9
Formal charge: 0

via PubChem

Article

12 sections

Contents

Medical uses
Adverse effects
Pharmacology
History
Society and culture
Legal status
Economics
Brand names
Research
Dasatinib+Quercetin
References
Further reading

Common adverse effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea. Severe adverse effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome. Use during pregnancy may result in harm to the fetus. It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.